From the Guidelines
Insulin is available in several types, including rapid-acting, short-acting, intermediate-acting, long-acting, and premixed insulins, each with distinct onset, peak, and duration of action. The types of insulin can be categorized as follows:
- Rapid-acting insulins, such as Humalog (insulin lispro), NovoLog (insulin aspart), and Apidra (insulin glulisine), which begin working within 15 minutes, peak in 1-2 hours, and last 2-4 hours, making them ideal for mealtime use 1.
- Short-acting or regular insulin, such as Humulin R and Novolin R, which starts working in 30 minutes, peaks in 2-3 hours, and lasts 3-6 hours.
- Intermediate-acting insulin, such as NPH (Humulin N, Novolin N), which has an onset of 2-4 hours, peaks in 4-12 hours, and lasts 12-18 hours 1.
- Long-acting insulins, such as Lantus (insulin glargine), Levemir (insulin detemir), and Tresiba (insulin degludec), which work over 24 hours with minimal peaks, providing basal coverage.
- Premixed insulins, which combine different types in fixed ratios, such as 70/30 or 75/25 mixtures of NPH and regular insulin, for convenience. The choice of insulin depends on individual blood glucose patterns, lifestyle, and treatment goals, with many patients using combinations of rapid-acting and long-acting insulins to mimic natural insulin secretion patterns 1.
From the FDA Drug Label
The FDA drug label does not answer the question.
From the Research
Types of Insulin
- Rapid-acting analogues:
- Insulin aspart
- Insulin lispro
- Insulin glulisine 2
- Basal analogues:
- Insulin glargine
- Insulin detemir 2
- Premixed insulin analogues:
- Human insulin:
- Inhaled insulins:
- Similar to regular insulin with respect to efficacy and safety, though small reversible changes in pulmonary function have been noted 2
Characteristics of Insulin Types
- Rapid-acting analogues: provide better postprandial glucose control and less hypoglycaemia than regular insulin 2
- Basal analogues: provide better fasting glucose control and less risk of hypoglycaemia than conventional human NPH insulin 2
- Premixed insulin analogues: improve postprandial glycemic control compared with human insulin mixes 4, 5